Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.
about
Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatmentDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Pathophysiology of manganese-associated neurotoxicityTetraspanin (TSP-17) protects dopaminergic neurons against 6-OHDA-induced neurodegeneration in C. elegansMeta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.Limb use and complex ultrasonic vocalization in a rat model of Parkinson's disease: deficit-targeted training.The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan AfricaThe Effect of Dopaminergic Medication on Joint Kinematics during Haptic Movements in Individuals with Parkinson's Disease.Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.Antioxidants as treatment for neurodegenerative disorders.Do dopamine agonists or levodopa modify Parkinson's disease progression?Medical management of Parkinson's disease: focus on neuroprotectionFeasibility of home-based automated Parkinson's disease motor assessment.Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties.Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design.Effects of STN DBS on memory guided force control in Parkinson's disease (June 2007)Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration.Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.Utility of tolcapone in fluctuating Parkinson's diseaseApomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.Imaging dopamine transporters in Parkinson's disease.The impact of subthalamic deep brain stimulation on nigral neuroprotection-myth or reality?Progression of motor symptoms in Parkinson's disease.Biomarkers for trials of neuroprotection in Parkinson's disease.Management of motor and non-motor symptoms in Parkinson's disease.Disease progression and neuroscience.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 2003-2013: Where are we another 10 years on?Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.Carbidopa levodopa enteral suspension.Disease progression, drug action and Parkinson's disease: why time cannot be ignored.Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.Neuroprotection in Parkinson's disease: love story or mission impossible?Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.Disease modification in Parkinson's disease.Interpreting the results of Parkinson's disease clinical trials: time for a change.Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.Neuroprotective treatment for Parkinson's disease.Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
P2860
Q24655595-99D71A06-5139-47BA-9BE4-CDED42880911Q27021464-6BC4C9E0-EC07-48EF-9A44-D2A52D73FDA7Q28384357-D17F55B5-2C16-4680-B733-63D38D91AE81Q28542478-03395F14-87DC-4CB4-BE4A-1DF7EC989BF3Q30480599-B2DBD32F-BEB8-4AA6-A485-57A3E0E307EEQ30487022-72F47BF2-8CE4-42A0-99A0-FDCEC6866620Q30586911-957CDBA8-DAFE-4BBB-9E94-26E8A1B58EA3Q33631207-6BC8B2A5-9F0A-4F9D-8134-7D7B7702A35FQ34272602-5921F8AE-BBCA-4D54-85F4-C6344E6B241DQ34974866-7494724C-9F46-4142-8465-DD87E8BA5571Q35015794-1BF5689F-F76B-422E-B80A-107F30F3AB19Q35092165-D413354A-33FC-4EFE-B679-82580801B32FQ35566252-E73D02B3-7F48-417E-861D-A879CB5B5837Q35623461-0171563F-1F1E-4555-8D33-FC6689E470B3Q36496485-08C7F6CA-0FC9-46DA-BE72-3D73A47B8C2EQ36614660-286A35AA-F496-436B-8031-83AB1C207269Q36703819-AC4E4F5B-0F87-4F73-895E-0F3568373ECBQ36989384-C72B5DF7-5EF3-46FB-B2C4-285A425C6941Q37018938-60D20174-7EFD-4EBA-8E7D-E396F30245B8Q37507973-69F781EB-3A31-4137-A29F-D3617731777AQ37800096-E086B90E-312A-487C-B73F-5E9B0BD978B5Q37944953-2A644B21-C38C-48CD-8C83-ABAA40A50250Q37974751-56BF9FF9-8998-4670-9FD6-50DEF4D41F95Q38038544-34A3E9E5-CBC3-414C-983A-510B0A78DEA0Q38091653-B4498618-F60E-449E-A6F4-3D76D6039B76Q38099584-CC9A9E55-B17F-45CC-BD30-EFF6F7CF715FQ38215506-CEE59C47-053F-4FF1-A066-0F987CC3E6C0Q38331824-43CA9A39-C5FA-4DBF-921C-A630EE0E2E7AQ38530328-806941D6-2E2A-4CFF-87F8-15B83F30E839Q38643494-583C44F2-BC61-4EAB-97A6-959DD6E6BAFDQ42226525-BF92A9FE-180B-4E7A-8529-D7314C643E9AQ42609024-5C84EE56-CED1-4C9F-B1AD-A4B62581C969Q43265626-9DEFA5F5-0183-4EDD-9D51-8C12E22B2093Q44165254-0CE5A606-4A34-40C1-A689-7065A826A070Q44713421-EEDDED8C-B4D0-4FC3-9C58-F82142FA121CQ45797972-110FAB6C-833B-44AD-8CE4-6DF57300782DQ45985296-C718C701-2C2E-4D91-ACD4-FA52CB711E83Q46416657-215FD85A-EE62-4C3B-8E44-A92AF60953E5Q47352832-28D7DECC-E46A-4303-98B8-CC082815D776Q48133239-DA2481EA-A37D-421B-9F42-45366F8C8027
P2860
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Parkinson disease, the effect ...... rial. Earlier vs Later L-DOPA.
@ast
Parkinson disease, the effect ...... rial. Earlier vs Later L-DOPA.
@en
type
label
Parkinson disease, the effect ...... rial. Earlier vs Later L-DOPA.
@ast
Parkinson disease, the effect ...... rial. Earlier vs Later L-DOPA.
@en
altLabel
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
@en
prefLabel
Parkinson disease, the effect ...... rial. Earlier vs Later L-DOPA.
@ast
Parkinson disease, the effect ...... rial. Earlier vs Later L-DOPA.
@en
P1433
P1476
Parkinson disease, the effect ...... rial. Earlier vs Later L-DOPA.
@en
P304
P356
10.1001/ARCHNEUR.56.5.529
P50
P577
1999-05-01T00:00:00Z